ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

PROK Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ProKidney Corp.NASDAQ: PROK

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -535.0%

Gross margin was -535.0% in Q1 FY2026, down 635.0 pp from a year earlier. On a trailing-twelve-month basis it was -224.4%, down 324.4 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-535.0%+9.0 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
-224.4%-324.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-635.0 pp——
1 year+0.0 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How PROK compares with its peers on the latest reported figures

  • PROK's LTM Mar 2026 gross margin of -224.4% is the lowest of the 4 companies compared; the peer median is 91.9%.
  • Its year-over-year change of -324.4 pp is the lowest of 4, against a peer median of -8.0 pp.
PROK Competitors Peer median
Gross Margin for PROK and competitors
Company Period LTM level YoY 3-year change
MAZEMaze Therapeutics, Inc.LTM Mar 202692.0% -8.0 pp—
ARDXArdelyx, Inc.LTM Mar 202691.9% +7.7 pp-2.6 pp
TVTXTravere Therapeutics, Inc.LTM Sep 202660.7% -37.0 pp+1.9 pp
PROKProKidney Corp.LTM Mar 2026-224.4% -324.4 pp—
DMACDiaMedica Therapeutics Inc.FY2025— ——
MENSJyong Biotech Ltd. Ordinary SharesFY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
Peer median (excluding PROK) 91.9%-8.0 pp-0.3 pp

Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00076K893K
Cost of Revenue00000
Gross Profit00076K893K
Gross Margin———100.0%100.0%
Research & Development46.26M82.07M106.71M127.67M114.12M
Selling, General & Admin8.86M70.94M44.82M56.08M51.78M
Operating Expenses55.11M153.01M151.52M183.75M165.9M
Depreciation & Amortization1.98M3.04M3.85M5.43M6.58M
EBITDA(53.12M)(143.99M)(125.59M)(158.49M)(144.62M)
EBITDA Margin———-208542.1%-16194.7%
Operating Income(55.11M)(153.01M)(151.52M)(183.68M)(165.01M)
Operating Margin———-241678.9%-18477.8%
Interest Income2K5.98M22.08M19.75M13.81M
Interest Expense0215K12K9K4K
Other Income / Expenses2K5.77M22.07M19.74M13.81M
Income Before Tax(55.11M)(147.24M)(129.45M)(163.93M)(151.2M)
Pre-Tax Margin———-215701.3%-16931.5%
Income Tax Expense38K896K6M(598K)414K
Net Income(55.15M)(108.03M)(35.47M)(61.19M)(68.99M)
Net Margin———-80507.9%-7725.2%
EPS (Basic)(1.73)(1.76)(0.57)(0.62)(0.52)
EPS (Diluted)(1.73)(1.76)(0.57)(0.62)(0.52)
Weighted Avg Shares31.89M61.54M61.71M97.92M133.94M
Weighted Avg Shares (Diluted)31.89M61.54M61.71M97.92M133.94M

ProKidney Corp.

NASDAQ:PROK

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.